Compositions and methods for inhibiting expression of factor v leiden mutant gene

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.

1 . A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Factor V Leiden mutant gene in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding Factor V Leiden mutant, and wherein said region of complementarity is less than 30 nucleotides in length and wherein said dsRNA, upon contact with a cell expressing said Factor V Leiden mutant, inhibits expression of said Factor V Leiden mutant gene by at least 20%. 
     
     
         2 . The dsRNA of  claim 1 , wherein said first sequence is selected from the group consisting of Table 1 and said second sequence is selected from the group consisting of Table 1. 
     
     
         3 . The dsRNA of  claim 1 , wherein said dsRNA comprises at least one modified nucleotide. 
     
     
         4 . The dsRNA of  claim 2 , wherein said dsRNA comprises at least one modified nucleotide. 
     
     
         5 . The dsRNA of  claim 3 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. 
     
     
         6 . The dsRNA of  claim 3 , wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. 
     
     
         7 . The dsRNA of  claim 3 , wherein said first sequence is selected from the group consisting of Table 1 and said second sequence is selected from the group consisting of Table 1. 
     
     
         8 . The dsRNA of  claim 6 , wherein said first sequence is selected from the group consisting of Table 1 and said second sequence is selected from the group consisting of Table 1. 
     
     
         9 . A cell comprising the dsRNA of  claim 1 . 
     
     
         10 . A pharmaceutical composition for inhibiting the expression of the Factor V Leiden mutant gene in an organism, comprising a dsRNA and a pharmaceutically acceptable carrier, wherein the dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding Factor V Leiden mutant, and wherein said region of complementarity is less than 30 nucleotides in length and wherein said dsRNA, upon contact with a cell expressing said Factor V Leiden mutant, inhibits expression of said Factor V Leiden mutant gene by at least 20%. 
     
     
         11 . The pharmaceutical composition of  claim 10 , wherein said first sequence of said dsRNA is selected from the group consisting of Table 1 and said second sequence of said dsRNA is selected from the group consisting of Table 1. 
     
     
         12 . The pharmaceutical composition of  claim 10 , wherein said first sequence of said dsRNA is selected from the group consisting of Table 1 and said second sequence of said dsRNA is selected from the group consisting of Table 1. 
     
     
         13 . A method for inhibiting the expression of the Factor V Leiden mutant gene in a cell, the method comprising:
 (a) introducing into the cell a double-stranded ribonucleic acid (dsRNA), wherein the dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding Factor V Leiden mutant, and wherein said region of complementarity is less than 30 nucleotides in length and wherein said dsRNA, upon contact with a cell expressing said Factor V Leiden mutant, inhibits expression of said Factor V Leiden mutant gene by at least 20%; and   (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the Factor V Leiden mutant gene, thereby inhibiting expression of the Factor V Leiden mutant gene in the cell.   
     
     
         14 . A method of treating, preventing or managing thrombophilia comprising administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a dsRNA, wherein the dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a mRNA encoding Factor V Leiden mutant, and wherein said region of complementarity is less than 30 nucleotides in length and wherein said dsRNA, upon contact with a cell expressing said Factor V Leiden mutant, inhibits expression of said Factor V Leiden mutant gene by at least 20%. 
     
     
         15 . A vector for inhibiting the expression of the Factor V Leiden mutant gene in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of a dsRNA, wherein one of the strands of said dsRNA is substantially complementary to at least a part of a mRNA encoding Factor V Leiden mutant and wherein said dsRNA is less than 30 base pairs in length and wherein said dsRNA, upon contact with a cell expressing said Factor V Leiden mutant, inhibits the expression of said Factor V Leiden mutant gene by at least 20%. 
     
     
         16 . A cell comprising the vector of  claim 15 .